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Objectives: Besiﬂoxacin is a novel ﬂuoroquinolone that was recently approved for topical treatment of bacterial
conjunctivitis. The compound was shown to be active in vitro against a broad spectrum of bacteria, including
isolates resistant to other antibacterials. Here, the bactericidal activity of besiﬂoxacin was evaluated against the
most common bacterial conjunctivitis pathogens.
Methods: MIC, MBC and time–kill experiments with besiﬂoxacin and comparators were performed according to
CLSI guidelines. Quinolone resistance-determining regions (QRDRs) were sequenced using standard PCR-based
techniques.
Results: MIC and MBC data indicated that besiﬂoxacin was the most potent ﬂuoroquinolone tested against
Staphylococcus aureus (n¼30), Staphylococcus epidermidis (n¼15) and Streptococcus pneumoniae (n¼35),
while all ﬂuoroquinolones were highly active against Haemophilus inﬂuenzae (n¼40). Besiﬂoxacin MBC:MIC
ratios were ≤4 for 97.5% of all isolates tested (n¼120). All ﬂuoroquinolones tested, as well as tobramycin,
were bactericidal, while azithromycin was bactericidal against S. pneumoniae and H. inﬂuenzae, but
bacteriostatic against the staphylococci. Time–kill assays with all four species showed that besiﬂoxacin
caused ≥1000-fold killing within 2 h for 11 of 12 isolates. Only one isolate treated with moxiﬂoxacin and
three ciproﬂoxacin-treated isolates achieved the same level of bactericidal activity under the same conditions.
Unlike the comparator ﬂuoroquinolones, besiﬂoxacin maintained a high potency and bactericidal activity even
against strains that contained multiple mutations in the genes encoding DNA gyrase and topoisomerase IV.
Conclusions: Overall, besiﬂoxacin demonstrated rapid bactericidal activity against the four major human
pathogens tested here, including isolates that showed in vitro resistance to other ﬂuoroquinolones,
b-lactams, macrolides or aminoglycosides.
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Introduction
Fluoroquinolones are widely used bactericidal drugs, and several
are approved for the treatment of bacterial conjunctivitis.
1 Besi-
ﬂoxacin is a novel member of the ﬂuoroquinolone class of anti-
bacterial agents that was recently approved for topical
treatment of bacterial conjunctivitis. The compound demon-
strates potent antibacterial activity in vitro against a wide
range of pathogens including Gram-positive and -negative
aerobic and anaerobic bacteria.
2 To date, besiﬂoxacin studies
have reported primarily MIC results, which deﬁne only the inhibi-
tory, or bacteriostatic, nature of an agent’s activity. While bacter-
iostatic agents can be sufﬁcient to eradicate some bacterial
infections, bactericidal agents may have an advantage in immu-
noprivileged sites such as the eye.
This study was conducted to assess how time and concen-
tration of drug exposure, as well as mutations that confer resist-
ance to other ﬂuoroquinolones, inﬂuence the bactericidal activity
of besiﬂoxacin. Accordingly, MBC, time–kill and molecular
sequencing experiments were performed with recent ocular iso-
lates of Staphylococcus aureus, Staphylococcus epidermidis,
Streptococcus pneumoniae and Haemophilus inﬂuenzae, which
are the four most prevalent bacterial conjunctivitis pathogens.
Similar to tobramycin and other ﬂuoroquinolones used for
ophthalmic indications, besiﬂoxacin showed low MBC:MIC ratios
typical of bactericidal agents. However, compared with
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1441moxiﬂoxacin and ciproﬂoxacin, besiﬂoxacin demonstrated overall
improved bactericidal potency and speed of action against both
ﬂuoroquinolone-susceptible (FQS) and ﬂuoroquinolone-resistant
(FQR) isolates of the four species tested.
Materials and methods
Bacterial isolates
Isolates were collected by Euroﬁns Medinet (Chantilly, VA, USA). The test
organisms for the MBC:MIC assays were recent (2006–07), predomi-
nantly ocular, isolates of United States origin, with the exception of
one FQR strain isolated in 2005. Isolates consisted of non-consecutive,
non-duplicate clinical isolates collected from .50 sites distributed
across the USA. Isolates were selected to provide a geographically
diverse challenge set that reﬂected current rates of important resistance
phenotypes [e.g. methicillin-resistant S. aureus (MRSA), ﬂuoroquinolone
resistance etc.] among ocular pathogens. The only non-ocular isolates
were the ATCC quality control strains (listed below) and the FQR
S. pneumoniae and H. inﬂuenzae isolates due to the rarity of these phe-
notypes. Overall, a total of 30 S. aureus and 15 S. epidermidis (including
methicillin- and ciproﬂoxacin-resistant isolates), 35 S. pneumoniae
(including penicillin-intermediate and -resistant isolates and a
levoﬂoxacin-resistant isolate) and 40 H. inﬂuenzae (including
b-lactamase-positive isolates) were tested. Quality control strains were
S. aureus ATCC 29213, S. aureus ATCC 25923, S. pneumoniae ATCC
49619 and H. inﬂuenzae ATCC 49247.
For time–kill assays, individual isolates with speciﬁc resistance pheno-
types were selected from the ocular pathogens described above. In
addition, a non-ocular isolate of H. inﬂuenzae was included to represent
the rare b-lactamase-negative, moxiﬂoxacin non-susceptible phenotype.
The test organisms included four isolates each of S. aureus and
S. epidermidis that were methicillin susceptible (MSSA and MSSE, respect-
ively) or methicillin resistant (MRSA and MRSE, respectively) and that were
FQS or FQR. In addition, two isolates of S. pneumoniae (both penicillin
susceptible, but FQS or FQR) and two isolates of H. inﬂuenzae [both
b-lactamase negative, but FQS or ﬂuoroquinolone non-susceptible
(FQNS)] were evaluated.
Antibacterial drugs
The sources of the test agents were as follows: besiﬂoxacin (Bausch +
Lomb, Inc., Rochester, NY, USA); levoﬂoxacin (Johnson & Johnson, Inc.,
Langhorne, PA, USA); penicillin, oxacillin and tobramycin (Sigma-Aldrich,
St Louis, MO, USA); and ceftazidime, azithromycin, ciproﬂoxacin, moxi-
ﬂoxacin and gatiﬂoxacin (TREK Diagnostic Systems, Inc., Cleveland,
OH, USA).
MIC and MBC determination
MICs were determined by broth microdilution using frozen panels per
CLSI reference methods and antibacterial susceptibilities were reported
using CLSI interpretive criteria.
3–5 The highest drug concentration
tested in this assay was 32 mg/L for tobramycin and 8 mg/L for the ﬂuor-
oquinolones and azithromycin. Prior to incubation, growth control wells
were sampled and plated to conﬁrm the initial inocula. After primary
incubation, MICs were recorded, and MBCs were determined by spotting
10 mL from wells at and above MICs on drug-free agar medium. The cfu
results from sampled test wells were used to determine MBCs that
caused ≥3 log bacterial killing.
3
Time–kill assay methodology
Time–kill assays were performed at 1×,2 ×,4 × and 8× MIC values per
CLSI methods.
3 Brieﬂy, growth-phase bacterial cultures at 5×10
5 to
5×10
6 cfu/mL were treated with antibacterial agents, and cfu were
determined at 0, 2, 4, 6 and 24 h. For time–kill experiments, bactericidal
activity was deﬁned as a ≥3 log decrease in cfu/mL 24 h after treatment.
Molecular characterization of FQR strains used in
time–kill assays
The molecular basis of ﬂuoroquinolone resistance was investigated in the
six FQR isolates used for time–kill experiments. The quinolone resistance-
determining regions (QRDRs) of DNA gyrase (gyrA and gyrB) and topoi-
somerase IV (parC and parE, also known as grlA and grlB), which are
commonly associated with ﬂuoroquinolone resistance, were ampliﬁed
and sequenced as described in the Supplementary methods [available
as Supplementary data at JAC Online (http://jac.oxfordjournals.org/)].
Results
Table 1 summarizes the MIC and MBC values of besiﬂoxacin and
comparators for 120 isolates of the four most prevalent ocular
pathogens. Where appropriate, b-lactam-resistant, macrolide-
resistant or FQR isolates were included in the sample population
to reﬂect current antibacterial resistance trends. Eleven of 30
S. aureus and 6 of 15 S. epidermidis isolates were resistant to
ciproﬂoxacin. Since the MIC or MBC values in some cases
exceeded the highest drug concentration tested, MBC:MIC
ratios could not be calculated for all isolates and thus some
MIC90 or MBC90 values were reported as .8. For the Gram-
positive pathogens, besiﬂoxacin and, to a lesser extent, moxiﬂox-
acin had the lowest MIC50 and MBC50 values of all agents tested.
Against H. inﬂuenzae, ciproﬂoxacin and gatiﬂoxacin were the
most active drugs, followed closely by besiﬂoxacin and moxiﬂox-
acin. MBC:MIC ratios were ≤4 for most antibacterial agents and
test strains, indicating a bactericidal mode of action. The only
exception was azithromycin, which was bacteriostatic against
S. aureus and S. epidermidis.
Time–kill assays were conducted for 12 isolates of FQS and
FQR bacteria at concentrations that were 1×,2 ×,4 × and 8×
the respective MIC. Figure 1 shows representative examples of
the concentration-dependent killing of FQS and FQR S. aureus
strains 2, 4, 6 and 24 h after the addition of besiﬂoxacin.
Similar results were obtained for the other 10 test isolates
after accounting for differences in their MICs [see Figure S1, avail-
able as Supplementary data at JAC Online (http://jac.
oxfordjournals.org/)].
The relationship between drug concentration and the
decrease in cfu 2 h after treatment with 1×,2 ×,4 × and 8× the
MIC of besiﬂoxacin, moxiﬂoxacin and ciproﬂoxacin is shown in
Figure 2.
Besiﬂoxacin had the lowest MIC values for S. aureus and
S. epidermidis and was the only agent that was able to reduce
thecfuby.1000-foldafter2 h(Figure2a–d).Highlevelsofresist-
ance prevented the testing of ciproﬂoxacin at 4×and 8×the MIC
for FQR isolates of S. aureus (Figure 2b). Ciproﬂoxacin was not
able to reduce the number of viable cells of FQR S. aureus and
S. epidermidis (Figure 2b and d). The potency and bactericidal
activity of moxiﬂoxacin falls between that of besiﬂoxacin and
ciproﬂoxacin. Resistance to methicillin (oxacillin) in S. aureus and
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Figure 1. Change in cfu/mL over time after the addition of besiﬂoxacin. The methicillin- and ciproﬂoxacin-susceptible S. aureus (MSSA-FQS) isolate
1711525 (a) and the methicillin- and ciproﬂoxacin-resistant S. aureus (MRSA-FQR) isolate 1711529 (b) were treated with 1× (ﬁlled circles), 2×
(open circles), 4× (ﬁlled diamonds) or 8× (open diamonds) the MIC of besiﬂoxacin. MIC values were 0.03 mg/L for strain 1711525 and 1 mg/L for
strain 1711529. A no-treatment growth control is identiﬁed by ﬁlled triangles. A 3 log reduction in viable cells is indicated by a continuous
horizontal line.
Table 1. In vitro activity and MBC:MIC ratios of besiﬂoxacin and comparator agents against ocular isolates of S. aureus, S. epidermidis,
S. pneumoniae and H. inﬂuenzae
Organism (number
of isolates)
Test
agent
MIC and MBC values for 50% and 90% of all
isolates (N)
Number (n) of MIC:MBC
ratios obtained
a
Percentage of n with
MBC:MIC ratios ≤2
Percentage of n with
MBC:MIC ratios ≤4
MIC50
(mg/L)
MBC50
(mg/L)
MIC90
(mg/L)
MBC90
(mg/L)
S. aureus (N¼30) BES 0.03 0.06 4 4 30 83.3 90.0
MXF 0.06 0.06 .8 .8 25 84.0 84.0
GAT 0.06 0.25 .8 .8 26 80.8 92.3
CIP 0.5 1 .8 .8 21 76.2 90.5
AZM 1 .8 .8 .8 10 10.0 20.0
TOB 0.5 1 .32 .32 24 75.0 91.7
S. epidermidis
(N¼15)
BES 0.03 0.06 4 4 15 93.3 100.0
MXF 0.06 0.12 .8 .8 12 91.7 100.0
GAT 0.06 0.12 .8 .8 12 83.3 100.0
CIP 0.12 0.25 .8 .8 10 90.0 100.0
AZM .8 .8 .8 .8 3 33.3 33.3
TOB 0.06 0.12 8 16 14 85.7 100.0
S. pneumoniae
(N¼35)
BES 0.06 0.06 0.06 0.12 35 97.1 100.0
MXF 0.06 0.12 0.12 0.25 35 91.4 100.0
GAT 0.12 0.25 0.25 0.5 35 100.0 100.0
CIP 0.5 1 1 2 34 100.0 100.0
AZM 0.06 0.25 .8 .8 25 68.0 92.0
TOB 16 32 32 64 35 88.6 100.0
H. inﬂuenzae
(N¼40)
BES 0.015 0.015 0.015 0.03 40 92.5 100.0
MXF 0.015 0.03 0.03 0.03 40 97.5 100.0
GAT 0.008 0.008 0.008 0.015 40 97.5 100.0
CIP 0.008 0.015 0.008 0.015 40 100.0 100.0
AZM 0.5 1 1 4 38 73.7 89.5
TOB 2 2 4 4 40 100.0 100.0
BES, besiﬂoxacin; MXF, moxiﬂoxacin; GAT, gatiﬂoxacin; CIP, ciproﬂoxacin; AZM, azithromycin; TOB, tobramycin.
aMIC50, MBC50, MIC90 and MBC90 values were determined based on all isolates (N) tested for one species. Because some MIC or MBCvalues were higher
than the tested range, the number of isolates (n) that yielded an MBC:MIC ratio was in some cases lower than the total number of isolates (N). The
percentage of isolates with MBC:MIC ratios ≤4 was based only on the number of isolates that yielded MIC and MBCvalues within the test range (n).
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Figure 2. Change in cfu/mL 2 h after the addition of 1×,2 ×,4 ×or 8×the MIC of besiﬂoxacin (ﬁlled circles), moxiﬂoxacin (open squares) or ciproﬂoxacin
(open triangles). A 3 log reduction in viable cells is indicated by a continuous horizontal line. (a) S. aureus (MRSA-FQS). (b) S. aureus (MSSA-FQR).
(c) S. epidermidis (MRSE-FQS). (d) S. epidermidis (MSSE-FQR). (e) S. pneumoniae (PSSP-FQS). (f) S. pneumoniae (PSSP-FQR). (g) H. inﬂuenzae
(BLNHI-FQS). (h) H. inﬂuenzae (BLNHI-FQNS). PSSP, penicillin-susceptible S. pneumoniae; BLNHI, b-lactamase-negative H. inﬂuenzae.
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quinolones, since methicillin-susceptible and -resistant strains
had similar time–kill proﬁles [see Figure S2, available as Sup-
plementary data at JAC Online (http://jac.oxfordjournals.org/)].
Against the FQS isolate of S. pneumoniae (Figure 2e), besiﬂoxa-
cin exhibited killing that was more rapid than that of either moxi-
ﬂoxacin or ciproﬂoxacin. Bactericidal activity against the FQR
isolate was greater for ciproﬂoxacin than the other test agents;
however, the ciproﬂoxacin MIC values were 16-fold higher than
those of moxiﬂoxacin and 128-fold higher than those of besiﬂox-
acin(Figure2f).A1000-foldreductionincfuwasobservedafter6 h
for besiﬂoxacin and 24 h for moxiﬂoxacin (data not shown).
Rapid bactericidal activity was observed against the FQS
isolate of H. inﬂuenzae (Figure 2g), where ciproﬂoxacin had a
2-fold lower MIC value than besiﬂoxacin and moxiﬂoxacin.
However, against the FQNS isolate, besiﬂoxacin killed more
rapidly than the other agents and did so at a concentration
that was 8- to 16-fold lower than the comparators.
The nucleotide sequences of the QRDRs of the gyrA, gyrB, parC
and parE genes for the six FQR isolates examined in the time–kill
assays were determined and compared with those previously
published for FQS strains; only nucleotide substitutions that
were not present in any of the FQS reference strains are shown
in Table 2. Codon 84 of GyrA in the staphylococci and
H. inﬂuenzae, and the corresponding codon 81 in S. pneumoniae,
encodes a Ser residue in FQS isolates. This was changed to a
Leu, Phe or Tyr in the six FQR strains. Similarly, Ser-80 of the
staphylococcal ParC (Ser-79 in S. pneumoniae and Ser-84 in
H. inﬂuenzae) was replaced by a Tyr, Phe or Arg residue in FQR
strains. While no other mutations were found in S. epidermidis,
additional amino acid changes in gyrA, parC or parE were
found in FQR isolates of S. aureus, S. pneumoniae and H. inﬂuen-
zae. Across all four species listed in Table 2, besiﬂoxacin was 4- to
8-fold more potent than moxiﬂoxacin and 16- to 256-fold more
potent than ciproﬂoxacin against these FQR isolates.
Discussion
Besiﬂoxacinisanovelﬂuoroquinolonethatwasrecently(May2009)
approved as a topical agent for the treatment of bacterial
conjunctivitis. It was therefore of interest to assess the bactericidal
activity of besiﬂoxacin against the most common causes of this
disease. MIC and MBC results in this study conﬁrmed that besiﬂox-
acin had potent in vitro activity against clinical isolates of relevant
species,andbesiﬂoxacinwasalsothemostpotentﬂuoroquinolone
testedagainstS.aureus,S.epidermidisandS.pneumoniae.Besiﬂox-
acin, moxiﬂoxacin and ciproﬂoxacin all demonstrated similar,
potent activity against H. inﬂuenzae. MBC values of besiﬂoxacin
were within 4-fold of the MIC value for the majority of tested iso-
lates, which is consistent with other ﬂuoroquinolones shown to
be bactericidal.
6 There was no apparent correlation between the
besiﬂoxacinMBC:MICratiosandresistancetoeitherotherﬂuoroqui-
nolones or b-lactams such as methicillin (data not shown). The
MBC:MIC ratios observed for besiﬂoxacin were similar to those
observed for other ﬂuoroquinolones, although the MIC, MBC and
time–kill proﬁle of besiﬂoxacin generally reﬂected better potency
relative to the other ﬂuoroquinolone comparatorsamong FQR sub-
populations.SimilaractivityagainstFQRisolateswasalsoevidentin
a recent study that evaluated the antibacterial spectrum of besi-
ﬂoxacin against 40 Gram-positive and -negative species.
2 Com-
pared with FQS isolates, MIC values for FQR isolates generally
increasedtoalesserdegreeforbesiﬂoxacinthanfortheotherﬂuor-
oquinolonestested.Thistrendofimproved activityagainst FQRiso-
lates was observed for various species of streptococci,
staphylococci,Enterobacteriaceae,pseudomonadsandHaemophi-
lus sp.
2
Similar to the ﬂuoroquinolones, the MBC:MIC values showed
that tobramycin was bactericidal against all four species
tested. However, azithromycin was only bactericidal against
S. pneumoniae and H. inﬂuenzae, but bacteriostatic against the
staphylococci. This ﬁnding is consistent with previous reports,
which showed that azithromycin was bactericidal against some
species and bacteriostatic against others.
7,8 In addition, azithro-
mycin resistance was common among clinical isolates, necessi-
tating drug concentrations that made it impractical to measure
reliable MIC or MBC values for those isolates.
The time–kill assay results for selected isolates of S. aureus,
S. epidermidis, S. pneumoniae and H. inﬂuenzae demonstrated
the rapid bactericidal activity of besiﬂoxacin, regardless of
ﬂuoroquinolone resistance phenotype. Besiﬂoxacin achieved a
3 log kill for 11 of 12 isolates within 2 h and within 6 h for all
Table 2. Mutations associated with ﬂuoroquinolone resistance in FQR isolates tested in time–kill assays
Organism Strain (phenotype)
MIC (mg/L) QRDR mutation(s)
a
BES MXF CIP GyrA GyrB ParC ParE
S. aureus 1970149 (MSSA) 1 8 256 S84L none S80Y, E84G none
1711529 (MRSA) 1 8 256 S84L none S80Y, E84G none
S. epidermidis 1711557 (MSSE) 0.5 2 32 S84F none S80Y none
1711555 (MRSE) 0.5 2 32 S84Y none S80F none
S. pneumoniae 1115445 0.5 4 64 S81Y none S79Y, K137N none
H. inﬂuenzae 1408337 2 16 32 S84F, D88Y none S84R D420N, S458A, S474N
BES, besiﬂoxacin; MXF, moxiﬂoxacin; CIP, ciproﬂoxacin.
aCompared with reference strains (GenBank accession number): Newman (NC_009641), N315 (NC_002745) and NCTC 8325 (NC_007795); ATCC 12228
(NC_004461) and RP62A (NC_002976); TIGR4 (NC_003028), R6 (NC_003098) and G54 (NC_011072); and 86-028NP (NC_007146) and RdKW20
(NC_00090).
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JAC12 isolates. For many isolates, the proﬁle of bacterial killing
was more rapid than that of the other agents tested, even
though the concentration of besiﬂoxacin was in some cases
as much as 256-fold lower than the other ﬂuoroquinolone
comparators.
Besiﬂoxacin and moxiﬂoxacin maintained bactericidal activity
against S. aureus and S. epidermidis, regardless of the methicillin
or ﬂuoroquinolone resistance phenotype of the isolate. This is in
contrast to ciproﬂoxacin, where only a bacteriostatic effect was
observed against FQR isolates. Similar results were reported by
Ince et al.,
9 who noted that ciproﬂoxacin was similar to moxiﬂox-
acin in killing a ‘moderately resistant’ strain of S. aureus contain-
ing one Ser-80 Phe mutation in ParC. However, against a ‘highly
resistant’ strain containing GyrA (Ser-84 Leu) and ParC
(Ser-80 Phe) mutations, moxiﬂoxacin maintained bactericidal
activity, while ciproﬂoxacin was bacteriostatic.
9 All four FQR iso-
lates of S. aureus and S. epidermidis in the present time–kill study
contained a Ser-84 mutation in GyrA and a Ser-80 mutation in
ParC. In addition, the two S. aureus isolates contained an
additional Glu-84 mutation in ParC, which might account for
the higher MIC values compared with the two S. epidermidis iso-
lates or the strain used by Ince et al.
9
Besiﬂoxacin and, to a lesser extent, moxiﬂoxacin, were the
most potent agents against FQS and FQR S. pneumoniae isolates,
while ciproﬂoxacin had 8- to 128-fold higher MICvalues. Besiﬂox-
acin was the fastest killing drug against the FQS S. pneumoniae
isolate, while ciproﬂoxacin was the most rapidly bactericidal
agent against FQR S. pneumoniae. However, the required drug
concentration was 16- to 128-fold higher than that of moxiﬂox-
acin and besiﬂoxacin, respectively. All three agents were rapidly
bactericidal against FQS H. inﬂuenzae. With the exception of
ciproﬂoxacin at 256 mg/L, besiﬂoxacin was the only agent that
was able to reduce the number of viable cells by .99.9% after
2 h. The time–kill kinetics of FQNS H. inﬂuenzae have not been
studied in great detail and this is the ﬁrst report that compares
the bactericidal activity of besiﬂoxacin with that of moxiﬂoxacin
and ciproﬂoxacin. Our results show that besiﬂoxacin and moxi-
ﬂoxacin are bactericidal against FQS and FQR isolates of
S. aureus, S. epidermidis, S. pneumoniae and H. inﬂuenzae;
however, besiﬂoxacin is active at equal or, in most cases, lower
absolute drug concentrations.
Nucleotide sequencing of the QRDRs of gyrA, gyrB, parC and
parE genes of the FQR isolates used for time–kill assays
showed that each of the six strains, regardless of the species,
contained at least two mutations. The Gram-positive species
S. aureus, S. epidermidis and S. pneumoniae all contained one
mutation in GyrA and one or two mutations in ParC, but no
mutations in GyrB or ParE were observed. The H. inﬂuenzae
isolate contained two mutations in GyrA and one mutation in
ParC. While no GyrB mutations were found in this isolate, ParE
contained three amino acid substitutions. Work by various inves-
tigators has found the same mutations described here and have
shown that, while individual mutations can increase resistance
to ﬂuoroquinolones, high-level resistance is the result of multiple
mutations that involve GyrA and ParC.
10–18 Despite those mul-
tiple mutations, besiﬂoxacin, and to a lesser extent moxiﬂoxacin,
maintained low MICs and potent bactericidal activity in the 24 h
test period. In contrast, ciproﬂoxacin had notably higher MIC
values for all species tested and lost bactericidal activity
against FQR isolates of S. aureus and S. epidermidis.
Depending upon the pathogen, earlier generation ﬂuoroqui-
nolones, such as ciproﬂoxacin, preferably target either DNA
gyrase or topoisomerase IV.
19 Subsequent ﬂuoroquinolones,
such as moxiﬂoxacin, and now besiﬂoxacin, have shown pro-
gressively more balanced dual targeting activity, often inhibiting
both enzymes with similar afﬁnity.
19 As a result, bacteria usually
must accumulate two or more mutations to exhibit substantial
in vitro resistance to the newer ﬂuoroquinolones. Taken together
with previous genetic and biochemical studies,
19 the sequencing
and MIC data presented here support the hypothesis that besi-
ﬂoxacin has well-balanced dual targeting activity, since the besi-
ﬂoxacin MICs were relatively low (0.5–2 mg/L) for strains with
multiple QRDR mutations that had ciproﬂoxacin MICs of 32–
256 mg/L.
Besiﬂoxacin has previously been shown to have a broad spec-
trum of antibacterial activity in vitro,
2 a favourable pharmacoki-
netic proﬁle in animal conjunctiva and corneal tissue, as well as
human tears,
20,21 and efﬁcacy in the treatment of bacterial con-
junctivitis in clinical trials of 0.6% besiﬂoxacin ophthalmic sus-
pension.
22–24 Following a single topical administration to
healthy human subjects, the maximum besiﬂoxacin concen-
tration in tear ﬂuid was 610 mg/g (i.e.  610 mg/L), with concen-
trations decreasing to  1.6 mg/g at 24 h.
20 Besiﬂoxacin
concentrations in human tear ﬂuid were sustained for at least
4 h at concentrations (approximately ≥85 mg/L) that were
.20-fold above the highest MIC90 or MBC90 value measured in
the present study for the four most prevalent ocular patho-
gens.
20 Following a single instillation, the total area under the
24 h concentration–time proﬁle (AUC24) for besiﬂoxacin in
human tear ﬂuid was 1263 mg.h/g.
20 Based on this single-dose
AUC24 estimate, an AUC24/MIC90 ratio of  316 was achieved
for S. aureus and S. epidermidis, and an AUC24/MIC90 ratio of
.21000 was obtained for S. pneumoniae and H. inﬂuenzae.
After a single dose, besiﬂoxacin exposure on the ocular surface
achieved Cmax/MIC and AUC24/MIC90 ratios that were well
above the generally accepted pharmacodynamic ratios required
for ﬂuoroquinolone efﬁcacy (i.e. Cmax/MIC90≥10 and AUC24/
MIC90≥30–50 for Gram-positive bacteria or ≥100–125 for
Gram-negative bacteria).
25–27 Taken together, these data indi-
cate that the rapid, concentration-dependent in vitro bactericidal
activity described here for besiﬂoxacin at concentrations ranging
from 0.015 to 8 mg/L are well within the clinically observed tear
concentrations of this agent, and further support the empirical
use of besiﬂoxacin for treating ocular surface infections.
20
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